TG Therapeutics Raises 2026 Revenue Guidance on BRIUMVI Momentum
Event summary
- TG Therapeutics reported $616.3M in total revenue for 2025, with BRIUMVI U.S. net revenue at $594.1M, up 92% YoY.
- 2026 revenue guidance raised to $875-900M, with BRIUMVI U.S. net product revenue expected at $825-850M.
- Completed $100M share repurchase program in Q3 2025, authorized new $100M program.
- Achieved 75% patient enrollment in Phase 3 pivotal program for subcutaneous ublituximab.
- Completed patient enrollment in Phase 3 ENHANCE trial for consolidated BRIUMVI dosing.
The big picture
TG Therapeutics' strong 2025 performance and raised 2026 guidance reflect BRIUMVI's growing adoption in relapsing multiple sclerosis (RMS). The company's strategic focus on pipeline advancements, including subcutaneous formulations and new indications, positions it to compete in the crowded anti-CD20 monoclonal antibody space. Success hinges on maintaining commercial momentum while managing operational costs and clinical trial timelines.
What we're watching
- Commercial Momentum
- Whether TG Therapeutics can sustain BRIUMVI's 20% quarterly growth and expand global availability beyond current markets.
- Pipeline Execution
- The pace at which TG Therapeutics advances its subcutaneous ublituximab and azer-cel programs, with pivotal data expected by year-end 2026.
- Financial Discipline
- How TG Therapeutics balances aggressive revenue targets with operating expenses, particularly manufacturing costs for subcutaneous BRIUMVI.
Related topics